• Foundation and Funding
  • International Affairs
  • PR and Marketing
  • Infrastructure
  • Biosamples and (Pre)clinic
  • Network
  • » 22.07.2015 US investors active again in Germany - focussing at Southern Germany
    leon-nanodrug (Munich; Series A-round up to €21m); Juno acquires Stage (Munich, Göttingen; €80m); Baxalta acquires Suppremol (Munich, €200m); Gates Foundation invests in CureVac (Tübingen; €60m)... » more
  • » 15.07.2015 3 Munich Biotech companies raise €100 mio in 5 days
    € 100 million capital increase in just 5 working days - what's going on in the Munich Biotech Cluster? » more
  • » 02.07.2015 Medigene AG secures over EUR 46mn from capital increase to finance its cancer immunotherapy programmes
    Medigene AG (MDG1, Frankfurt, Prime Standard) completed the capital increase announced on 12 June 2015 for the funding of its cancer immunotherapy programmes, achieving gross proceeds of approximately EUR 46.4 million by placing the maximum number of 5,594,178 new offered shares to existing shareholders and selected new institutional investors for... » more
  • » 22.06.2015 40 million euros for new protein research centre for Functional Protein Assemblies (CPA) in Munich
    Close-knit interplay of the various scientific disciplines and engineering services, as well as the planned transfer of research findings to medical applications was appealing to the Joint Science Conference who awarded this grant. The TUM is already active in the Cluster of Excellence “Center for Integrated Protein Science Munich (CIPSM)”, at the... » more
  • » 17.06.2015 Munich´s SIRION Biotech Plans Opening of a New Office in the Boston Area
    SIRION Biotech, a leading viral vector platform company known for creating high quality viral vector solutions for industry and academic partners, today announced its commitment to open a new office in the vicinity of Boston. » more
  • » 15.06.2015 Meet Bavarian Biotech expertise at BIO USA in Philadelphia
    Bavaria welcomes you at the German Pavillion! » more